(±)-Darifenacin-d4 (hydrobromide)

• UNSPSC Description:

  (±)-Darifenacin-d4 (hydrobromide) is deuterium labeled (±)-Darifenacin. (±)-Darifenacin is the racemate of Darifenacin. Darifenacin is a selective M3 muscarinic receptor antagonist[1].

• Target Antigen:

  Isotope-Labeled Compounds; mAChR

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling;Others

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Neurological Disease

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(C(C1=CC=CC=C1)(C2CN(CC2)C([2H])([2H])C([2H])([2H])C3=CC=C4OCCC4=C3)C5=CC=CC=C5)N.Br

• Molecular Weight:

  511.49

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Hegde SS, et al. Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol, 1997, 120(8), 1409-1418.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2747914-16-3